National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 3 of 3 Research Studies DisplayedOke I, Lutz SM, Hunter DG
Use and costs of instrument-based vision screening for US children aged 12 to 36 months.
This research letter describes a cohort study that examined patterns and out-of-pocket costs of instrument-based vision screening among US children 12 to 36 months. The authors used 2018 MarketScan Commerical Claims and Encounters data as of January 1, 2018 and excluded those with fewer than 12 months of continuous insurance coverage, enrollment in capitated insurance plans, no preventive care encounters, or missing data on residents. The study included 246,077 children. Instrument-based vision screening was received by 19.5% (n = 48,101) of children during 2018. Median (IQR) practitioner payment for instrument-based vision screening claims was $13. Screening incurred out-of-pocket expenses for 7% of children; 30% of these children had expenses related to co-payment, 20.2% to coinsurance, and 50.7% to deductibles. Median (IQR) out-of-pocket expense was $11. Increased odds of vision screening were associated with older age, high-deductible plan enrollment, having more than 1 preventative visit, and receiving care within an area in the highest quartile of practitioner payment. This study was limited by use of commercial claims data, which excluded 45% of children with public or no coverage. Nationwide prevalence of vision screening therefore may differ for the general population.
AHRQ-funded; HS000063.
Citation: Oke I, Lutz SM, Hunter DG .
Use and costs of instrument-based vision screening for US children aged 12 to 36 months.
JAMA Pediatr 2023 Jul; 177(7):728-30. doi: 10.1001/jamapediatrics.2023.0808..
Keywords: Newborns/Infants, Eye Disease and Health, Screening, Prevention, Healthcare Costs
Chou R, Selph S, Blazina I
Screening for glaucoma in adults: updated evidence report and systematic review for the US Preventive Services Task Force.
This evidence report and systematic review updated the 2013 USPSTF final recommendation to assess benefits and harms of screening for primary open-angle glaucoma (OAG) in adults. After an extensive literature review, 83 studies were included (30 trials and 53 diagnostic accuracy studies). One randomized clinical trial (RCT) found screening of frail elderly persons associated with no difference in vision outcomes vs no screening but with significantly greater falls risk. There was limited direct evidence on glaucoma screening, with no association of benefits.
AHRQ-funded; 290201500011I.
Citation: Chou R, Selph S, Blazina I .
Screening for glaucoma in adults: updated evidence report and systematic review for the US Preventive Services Task Force.
JAMA 2022 May 24;327(20):1998-2012. doi: 10.1001/jama.2022.6290..
Keywords: U.S. Preventive Services Task Force (USPSTF), Screening, Eye Disease and Health, Prevention, Guidelines, Evidence-Based Practice
Guirguis-Blake JM, Evans CV, Rushkin M
Ocular prophylaxis for gonococcal ophthalmia neonatorum: updated evidence report and systematic review for the US Preventive Services Task Force.
This evidence report and systematic review was commissioned for the U.S. Preventive Services Task Force to update the evidence of using prophylactic ocular topic medication for all newborns to prevent gonococcal ophthalmia neonatorum (GON) which can cause blindness if not treated immediately. Many articles were screened for inclusion, and of those included the recommendations remained an “A” grade recommendation, which is to apply the topical medication on all newborns due to an increase in syphilis prevalence.
AHRQ-funded; 290201500007I.
Citation: Guirguis-Blake JM, Evans CV, Rushkin M .
Ocular prophylaxis for gonococcal ophthalmia neonatorum: updated evidence report and systematic review for the US Preventive Services Task Force.
JAMA 2019 Jan 29;321(4):404-06. doi: 10.1001/jama.2018.17847..
Keywords: Evidence-Based Practice, Eye Disease and Health, Guidelines, Newborns/Infants, Prevention, U.S. Preventive Services Task Force (USPSTF)